

Martina Zimovjanova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/125136/publications.pdf>

Version: 2024-02-01

9
papers

1,846
citations

1478505

6
h-index

1588992

8
g-index

9
all docs

9
docs citations

9
times ranked

3075
citing authors

#	ARTICLE	IF	CITATIONS
1	Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers. <i>Aesthetic Plastic Surgery</i> , 2022, 46, 706-711.	0.9	7
2	Abstract P3-14-01: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis. , 2020, , .		0
3	Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers. <i>Cancers</i> , 2019, 11, 738.	3.7	22
4	Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. <i>International Journal of Cancer</i> , 2019, 145, 1782-1797.	5.1	62
5	The PALB2 Gene Is a Strong Candidate for Clinical Testing in BRCA1- and BRCA2-Negative Hereditary Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2323-2332.	2.5	42
6	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet</i> , The, 2013, 381, 805-816.	13.7	1,664
7	Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 337-347.	2.5	33
8	Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy – results from an expanded access programme. <i>European Journal of Cancer</i> , Supplement, 2004, 2, 132-133.	2.2	11
9	4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. <i>Bulletin Du Cancer</i> , 2004, 91, E279-83.	1.6	5